Mark E Williams1. 1. Joslin Diabetes Center, Harvard Medical School, Boston, Mass., USA. mark.williams@joslin.harvard.edu
Abstract
BACKGROUND/AIMS: Proteinuria, nearly a universal finding in progressive kidney disease, has been the subject of frequent recent analyses in the renal literature. Proteinuria is a hallmark of diabetic nephropathy: microalbuminuria is the principal early predictor for progression of diabetic glomerulopathy, and proteinuria may be viewed as a measure of the severity and promoter of progression of nephropathy. METHODS: This article critically reviews for the first time the full scope of diabetic proteinuria--complex molecular mechanisms, natural history, and analysis of treatment trials--in order to address the validity of 'the proteinuria hypothesis', i.e., that diabetic proteinuria is a modifiable determinant of renal progression. This hypothesis is analyzed in detail, including recent studies on the primary therapy of diabetic nephropathy, renin-angiotensin blockade. RESULTS: As fully developed, this hypothesis consists of three postulates: that higher amounts of proteinuria predict progressive loss of function, that proteinuria reduction correlates with slowing progression, and that proteinuria is a surrogate endpoint for clinical trials. The latter postulate has not before been adequately linked to growing information about the first two postulates as they apply to diabetic kidney disease. CONCLUSION: While diabetic nephropathy is a disease model for the potential use of proteinuria as a surrogate marker for renal progression, this shift in perspective will require prospective data from additional clinical trials, particularly of non-renin-angiotensin blocking drugs, to be complete. 2005 S. Karger AG, Basel
BACKGROUND/AIMS: Proteinuria, nearly a universal finding in progressive kidney disease, has been the subject of frequent recent analyses in the renal literature. Proteinuria is a hallmark of diabetic nephropathy: microalbuminuria is the principal early predictor for progression of diabetic glomerulopathy, and proteinuria may be viewed as a measure of the severity and promoter of progression of nephropathy. METHODS: This article critically reviews for the first time the full scope of diabetic proteinuria--complex molecular mechanisms, natural history, and analysis of treatment trials--in order to address the validity of 'the proteinuria hypothesis', i.e., that diabetic proteinuria is a modifiable determinant of renal progression. This hypothesis is analyzed in detail, including recent studies on the primary therapy of diabetic nephropathy, renin-angiotensin blockade. RESULTS: As fully developed, this hypothesis consists of three postulates: that higher amounts of proteinuria predict progressive loss of function, that proteinuria reduction correlates with slowing progression, and that proteinuria is a surrogate endpoint for clinical trials. The latter postulate has not before been adequately linked to growing information about the first two postulates as they apply to diabetic kidney disease. CONCLUSION: While diabetic nephropathy is a disease model for the potential use of proteinuria as a surrogate marker for renal progression, this shift in perspective will require prospective data from additional clinical trials, particularly of non-renin-angiotensin blocking drugs, to be complete. 2005 S. Karger AG, Basel
Authors: Bruce A Perkins; Ionut Bebu; Ian H de Boer; Mark Molitch; William Tamborlane; Gayle Lorenzi; William Herman; Neil H White; Rodica Pop-Busui; Andrew D Paterson; Trevor Orchard; Catherine Cowie; John M Lachin Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112
Authors: Bruce A Perkins; Linda H Ficociello; Bijan Roshan; James H Warram; Andrzej S Krolewski Journal: Kidney Int Date: 2010-01 Impact factor: 10.612
Authors: Maja T Lindenmeyer; Maria P Rastaldi; Masami Ikehata; Matthias A Neusser; Matthias Kretzler; Clemens D Cohen; Detlef Schlöndorff Journal: J Am Soc Nephrol Date: 2008-09-05 Impact factor: 10.121